{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T10:50:41Z","timestamp":1786791041747,"version":"build-2736575974"},"reference-count":105,"publisher":"Elsevier","isbn-type":[{"value":"9780128177822","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.vh.2018.10.008","type":"book-chapter","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T22:54:44Z","timestamp":1544568884000},"page":"151-188","source":"Crossref","is-referenced-by-count":8,"title":["Mineralocorticoid Receptor Antagonists"],"prefix":"10.1016","author":[{"given":"Anneli","family":"Nordqvist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"Granberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.vh.2018.10.008_bb0010","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"European Journal of Pharmacology"},{"issue":"3","key":"10.1016\/bs.vh.2018.10.008_bb0015","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1124\/jpet.116.234765","article-title":"CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate\/salt-induced hypertensive rats","volume":"358","author":"Arai","year":"2016","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.vh.2018.10.008_bb0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","article-title":"CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in dahl salt-sensitive hypertensive rats","volume":"769","author":"Arai","year":"2015","journal-title":"European Journal of Pharmacology"},{"issue":"10","key":"10.1016\/bs.vh.2018.10.008_bb0025","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1021\/jm1002827","article-title":"Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines","volume":"53","author":"Arhancet","year":"2010","journal-title":"Journal of Medicinal Chemistry"},{"issue":"16","key":"10.1016\/bs.vh.2018.10.008_bb0030","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1021\/jm100506y","article-title":"Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists","volume":"53","author":"Arhancet","year":"2010","journal-title":"Journal of Medicinal Chemistry"},{"issue":"8","key":"10.1016\/bs.vh.2018.10.008_bb0035","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"Baerfacker","year":"2012","journal-title":"ChemMedChem"},{"issue":"2","key":"10.1016\/bs.vh.2018.10.008_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"Bamberg","year":"2018","journal-title":"PLoS One"},{"issue":"26","key":"10.1016\/bs.vh.2018.10.008_bb0045","doi-asserted-by":"crossref","first-page":"6443","DOI":"10.1021\/jm701186z","article-title":"(S)-N-{3-[1-Cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: A potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor","volume":"50","author":"Bell","year":"2007","journal-title":"Journal of Medicinal Chemistry"},{"issue":"35","key":"10.1016\/bs.vh.2018.10.008_bb0050","doi-asserted-by":"crossref","first-page":"31283","DOI":"10.1074\/jbc.M504098200","article-title":"A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor","volume":"280","author":"Bledsoe","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.vh.2018.10.008_bb0055","series-title":"Preparation of pyridyl ureas as mineralocorticoid receptor antagonists, WO2012064631A1","author":"Boyer","year":"2012"},{"issue":"1","key":"10.1016\/bs.vh.2018.10.008_bb0060","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bmcl.2010.11.054","article-title":"Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist","volume":"21","author":"Brown","year":"2011","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/bs.vh.2018.10.008_bb0065","series-title":"WO2006012642A2","article-title":"Preparation of pyrrolecarboxamide derivatives as mineralocorticoid receptor antagonists for use against cancer and other disorders","author":"Canne Bannen","year":"2006"},{"issue":"10","key":"10.1016\/bs.vh.2018.10.008_bb0070","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1021\/jm500206r","article-title":"Identification of (R)-6-(1-(4-Cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist","volume":"57","author":"Casimiro-Garcia","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"issue":"2","key":"10.1016\/bs.vh.2018.10.008_bb0080","first-page":"1","article-title":"Pharmacological profile of KBP-5074, a novel NonSteroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal diseases","volume":"3","author":"Chow","year":"2017","journal-title":"The Journal of Drug Research and Development"},{"key":"10.1016\/bs.vh.2018.10.008_bb0085","series-title":"Preparation of dibenzooxepinylidenemethylhexahydropyrrolooxazinylbenzoimidazolone derivatives for use as mineralocorticoid receptor antagonists, WO2010104721A1","author":"Coates","year":"2010"},{"key":"10.1016\/bs.vh.2018.10.008_bb0090","series-title":"WO2004052847A2","article-title":"Preparation of derivatives of and analogs of dibenzosuberone for use in pharmaceutical compositions as steroid hormone nuclear receptor modulators","author":"Coghlan","year":"2004"},{"issue":"7","key":"10.1016\/bs.vh.2018.10.008_bb0095","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.bmcl.2014.02.057","article-title":"Mineralocorticoid receptor antagonists: Identification of heterocyclic amide replacements in the oxazolidinedione series","volume":"24","author":"Cox","year":"2014","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"2","key":"10.1016\/bs.vh.2018.10.008_bb0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08998280.2004.11927973","article-title":"Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure","volume":"17","author":"Craft","year":"2004","journal-title":"Proceedings (Baylor University Medical Center)"},{"issue":"17","key":"10.1016\/bs.vh.2018.10.008_bb0105","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT\u2014New insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"1B","key":"10.1016\/bs.vh.2018.10.008_bb0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0022-4731(89)90169-6","article-title":"Antialdosterones: Incidence and prevention of sexual side effects","volume":"32","author":"De Gasparo","year":"1989","journal-title":"Journal of Steroid Biochemistry"},{"issue":"3","key":"10.1016\/bs.vh.2018.10.008_bb0115","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","article-title":"A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity","volume":"51","author":"Dietz","year":"2008","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/bs.vh.2018.10.008_bb0120","first-page":"2280","article-title":"Ligand binding mechanism in steroid receptors: From conserved plasticity to differential evolutionary constraints","volume":"23","author":"Edman","year":"2015","journal-title":"Structure (Oxford, United Kingdom)"},{"key":"10.1016\/bs.vh.2018.10.008_bb0125","first-page":"381","article-title":"Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks","volume":"45","author":"Edwards","year":"2010","journal-title":"Annual Reports in Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.008_bb0130","series-title":"Preparation of fluorenone 1,4-dihydropyridine derivatives for use as cardiovascular agents, WO2005087740A1","author":"Ergueden","year":"2005"},{"issue":"39","key":"10.1016\/bs.vh.2018.10.008_bb0135","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"issue":"6","key":"10.1016\/bs.vh.2018.10.008_bb0140","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nsmb939","article-title":"Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension","volume":"12","author":"Fagart","year":"2005","journal-title":"Nature Structural & Molecular Biology"},{"issue":"23","key":"10.1016\/bs.vh.2018.10.008_bb0145","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1016\/j.bmcl.2013.09.099","article-title":"Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists","volume":"23","author":"Futatsugi","year":"2013","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"D1","key":"10.1016\/bs.vh.2018.10.008_bb9000","doi-asserted-by":"crossref","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","article-title":"ChEMBL: A large-scale bioactivity database for drug discovery","volume":"40","author":"Gaulton","year":"2012","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/bs.vh.2018.10.008_bb0150","series-title":"Preparation of dihydrobenzimidazoles containing dibenzo[b,e]oxepine moiety as mineralocorticoid receptor antagonists, US20090163472A1","author":"Gavardinas","year":"2009"},{"issue":"5476","key":"10.1016\/bs.vh.2018.10.008_bb0155","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1126\/science.289.5476.119","article-title":"Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy","volume":"289","author":"Geller","year":"2000","journal-title":"Science (Washington, D. C.)"},{"key":"10.1016\/bs.vh.2018.10.008_bb0160","author":"GOSTAR database"},{"key":"10.1016\/bs.vh.2018.10.008_bb0165","series-title":"Discovery of AZD9977: A non-steroidal mineralocorticoid modulator for treatment of diabetic kidney disease","author":"Granberg","year":"2017"},{"issue":"2","key":"10.1016\/bs.vh.2018.10.008_bb0170","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1021\/acs.oprd.6b00368","article-title":"Double heck route to a dibenzoxepine and convergent Suzuki cross-coupling strategy for the synthesis of an MR antagonist","volume":"21","author":"Hansen","year":"2017","journal-title":"Organic Process Research and Development"},{"issue":"24","key":"10.1016\/bs.vh.2018.10.008_bb0175","doi-asserted-by":"crossref","first-page":"8616","DOI":"10.1021\/jm2011645","article-title":"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists","volume":"54","author":"Hasui","year":"2011","journal-title":"Journal of Medicinal Chemistry"},{"issue":"19","key":"10.1016\/bs.vh.2018.10.008_bb0180","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1016\/j.bmc.2013.07.043","article-title":"Design, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists","volume":"21","author":"Hasui","year":"2013","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"19","key":"10.1016\/bs.vh.2018.10.008_bb0185","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1016\/j.bmc.2014.07.038","article-title":"Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists","volume":"22","author":"Hasui","year":"2014","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/bs.vh.2018.10.008_bb0190","series-title":"Preparation of heterocycles as mineralocorticoid receptor antagonist, WO2012022121A1","author":"Huang","year":"2012"},{"issue":"6","key":"10.1016\/bs.vh.2018.10.008_bb0195","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/me.2004-0537","article-title":"The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms","volume":"19","author":"Hultman","year":"2005","journal-title":"Molecular Endocrinology"},{"issue":"3","key":"10.1016\/bs.vh.2018.10.008_bb0200","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/mol.107.036459","article-title":"Structural basis of spirolactone recognition by the mineralocorticoid receptor","volume":"72","author":"Huyet","year":"2007","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.vh.2018.10.008_bb0205","author":"JapicCTI-173695"},{"key":"10.1016\/bs.vh.2018.10.008_bb0210","series-title":"Process for preparation of crystal form of mineralocorticoid receptor antagonist, WO2014094664A1","author":"Jiang","year":"2014"},{"issue":"6","key":"10.1016\/bs.vh.2018.10.008_bb0215","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.vh.2018.10.008_bb0220","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/03602537808993782","article-title":"Spironolactone: Disposition, metabolism, pharmacodynamics, and bioavailability","volume":"8","author":"Karim","year":"1978","journal-title":"Drug Metabolism Reviews"},{"key":"10.1016\/bs.vh.2018.10.008_bb0225","series-title":"Preparation of aromatic sulfone, sulfonamide, and sulfonate compounds as aldosterone receptor (mineralocorticoid receptor) (MR) modulators, WO2006077821A1","author":"Katayama","year":"2006"},{"issue":"4","key":"10.1016\/bs.vh.2018.10.008_bb0230","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cbpa.2006.06.014","article-title":"A practical view of druggability","volume":"10","author":"Keller","year":"2006","journal-title":"Current Opinion in Chemical Biology"},{"key":"10.1016\/bs.vh.2018.10.008_bb0235","series-title":"Preparation of 2,3-benzo-4-pyrones as mineralocorticoid receptor antagonists, WO2007009670A1","author":"Kuhl","year":"2007"},{"key":"10.1016\/bs.vh.2018.10.008_bb0240","series-title":"Preparation of chromone-substituted 1,4-dihydropyridines as antagonists of the mineralocorticoid receptor (MR) for treating cardiovascular diseases, DE102005034267A1","author":"Kuhl","year":"2007"},{"issue":"11","key":"10.1016\/bs.vh.2018.10.008_bb0245","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nature Reviews Drug Discovery"},{"issue":"6","key":"10.1016\/bs.vh.2018.10.008_bb0250","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.bmc.2016.02.014","article-title":"Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists","volume":"24","author":"Lotesta","year":"2016","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"40","key":"10.1016\/bs.vh.2018.10.008_bb0255","doi-asserted-by":"crossref","first-page":"35079","DOI":"10.1074\/jbc.M111.273029","article-title":"Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators","volume":"286","author":"Lusher","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/bs.vh.2018.10.008_bb0260","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jval.2012.01.004","article-title":"Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart failure","volume":"15","author":"McKenna","year":"2012","journal-title":"Value in Health"},{"issue":"16","key":"10.1016\/bs.vh.2018.10.008_bb0265","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm100505n","article-title":"Discovery of (3S,3aR)-2-(3-Chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy","volume":"53","author":"Meyers","year":"2010","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/bs.vh.2018.10.008_bb0270","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1254\/jphs.10285FP","article-title":"SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity","volume":"115","author":"Nariai","year":"2011","journal-title":"Journal of Pharmacological Sciences (Tokyo, Japan)"},{"issue":"1\u20132","key":"10.1016\/bs.vh.2018.10.008_bb0275","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000335559","article-title":"Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone\/salt-treated rats","volume":"89","author":"Nariai","year":"2012","journal-title":"Pharmacology"},{"issue":"5","key":"10.1016\/bs.vh.2018.10.008_bb0280","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/FJC.0b013e3182495543","article-title":"SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats","volume":"59","author":"Nariai","year":"2012","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/bs.vh.2018.10.008_bb0285","author":"NCT00971802"},{"key":"10.1016\/bs.vh.2018.10.008_bb0290","author":"NCT01314898"},{"key":"10.1016\/bs.vh.2018.10.008_bb0295","author":"NCT01427972"},{"key":"10.1016\/bs.vh.2018.10.008_bb0300","author":"NCT01488877"},{"key":"10.1016\/bs.vh.2018.10.008_bb0305","author":"NCT01756716"},{"key":"10.1016\/bs.vh.2018.10.008_bb0310","author":"NCT01807221"},{"key":"10.1016\/bs.vh.2018.10.008_bb0315","author":"NCT01874431"},{"key":"10.1016\/bs.vh.2018.10.008_bb0320","author":"NCT01889277"},{"key":"10.1016\/bs.vh.2018.10.008_bb0325","author":"NCT01955694"},{"key":"10.1016\/bs.vh.2018.10.008_bb0330","author":"NCT01968668"},{"key":"10.1016\/bs.vh.2018.10.008_bb0335","author":"NCT02194465"},{"key":"10.1016\/bs.vh.2018.10.008_bb0340","author":"NCT02205372"},{"key":"10.1016\/bs.vh.2018.10.008_bb0345","author":"NCT02228733"},{"key":"10.1016\/bs.vh.2018.10.008_bb0350","author":"NCT02300259"},{"key":"10.1016\/bs.vh.2018.10.008_bb0355","author":"NCT02345057"},{"key":"10.1016\/bs.vh.2018.10.008_bb0360","author":"NCT02448628"},{"key":"10.1016\/bs.vh.2018.10.008_bb0365","author":"NCT02484729"},{"key":"10.1016\/bs.vh.2018.10.008_bb0370","author":"NCT02517320"},{"key":"10.1016\/bs.vh.2018.10.008_bb0375","author":"NCT02532998"},{"key":"10.1016\/bs.vh.2018.10.008_bb0380","author":"NCT02540993"},{"key":"10.1016\/bs.vh.2018.10.008_bb0385","author":"NCT02545049"},{"key":"10.1016\/bs.vh.2018.10.008_bb0390","author":"NCT02653014"},{"key":"10.1016\/bs.vh.2018.10.008_bb0395","author":"NCT02676401"},{"key":"10.1016\/bs.vh.2018.10.008_bb0400","author":"NCT02807974"},{"key":"10.1016\/bs.vh.2018.10.008_bb0405","author":"NCT02808026"},{"key":"10.1016\/bs.vh.2018.10.008_bb0410","author":"NCT02837237"},{"key":"10.1016\/bs.vh.2018.10.008_bb0415","author":"NCT02885662"},{"key":"10.1016\/bs.vh.2018.10.008_bb0420","author":"NCT02890173"},{"key":"10.1016\/bs.vh.2018.10.008_bb0425","author":"NCT02923154"},{"key":"10.1016\/bs.vh.2018.10.008_bb0430","author":"NCT03435276"},{"key":"10.1016\/bs.vh.2018.10.008_bb0435","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/9783527677047.ch16","article-title":"Lead quality","volume":"68","author":"Nissink","year":"2016","journal-title":"Methods and Principles in Medicinal Chemistry"},{"issue":"1","key":"10.1016\/bs.vh.2018.10.008_bb0440","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/cmdc.201600529","article-title":"Structure-based drug design of mineralocorticoid receptor antagonists to explore oxosteroid receptor selectivity","volume":"12","author":"Nordqvist","year":"2017","journal-title":"ChemMedChem"},{"issue":"12","key":"10.1016\/bs.vh.2018.10.008_bb0445","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1016\/j.bmcl.2016.04.052","article-title":"Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists","volume":"26","author":"Ogawa","year":"2016","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"2","key":"10.1016\/bs.vh.2018.10.008_bb0450","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/acs.molpharmaceut.5b00840","article-title":"Validation of early human dose prediction: A key metric for compound progression in drug discovery","volume":"13","author":"Page","year":"2016","journal-title":"Molecular Pharmaceutics"},{"issue":"5","key":"10.1016\/bs.vh.2018.10.008_bb0455","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"Journal of Hypertension"},{"issue":"1","key":"10.1016\/bs.vh.2018.10.008_bb0460","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/bs.vh.2018.10.008_bb0465","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1021\/jm300806c","article-title":"Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy","volume":"55","author":"Piotrowski","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/bs.vh.2018.10.008_bb0470","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1021\/acs.jmedchem.7b01515","article-title":"Identification of morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as nonsteroidal mineralocorticoid antagonists","volume":"61","author":"Piotrowski","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"issue":"12","key":"10.1016\/bs.vh.2018.10.008_bb0475","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s10822-015-9880-1","article-title":"Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods","volume":"29","author":"Roos","year":"2015","journal-title":"Journal of Computer-Aided Molecular Design"},{"issue":"12","key":"10.1016\/bs.vh.2018.10.008_bb0480","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrneph.2012.217","article-title":"Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy","volume":"8","author":"Roscioni","year":"2012","journal-title":"Nature Reviews Nephrology"},{"issue":"15","key":"10.1016\/bs.vh.2018.10.008_bb0485","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1016\/j.bmcl.2009.05.062","article-title":"Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A lipophilic efficiency (LipE) analysis","volume":"19","author":"Ryckmans","year":"2009","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"9","key":"10.1016\/bs.vh.2018.10.008_bb0490","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1248\/cpb.28.2809","article-title":"Synthesis of optically active 2-(N-benzyl-N-methylamino)ethyl methyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (Nicardipine)","volume":"28","author":"Shibanuma","year":"1980","journal-title":"Chemical & Pharmaceutical Bulletin (Tokyo)"},{"issue":"16","key":"10.1016\/bs.vh.2018.10.008_bb0495","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1016\/j.bmcl.2009.06.055","article-title":"Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists","volume":"19","author":"Thompson","year":"2009","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"8","key":"10.1016\/bs.vh.2018.10.008_bb0500","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"American Journal of Hypertension"},{"issue":"7","key":"10.1016\/bs.vh.2018.10.008_bb0505","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1021\/jm021053p","article-title":"A comparison of physiochemical property profiles of development and marketed oral drugs","volume":"46","author":"Wenlock","year":"2003","journal-title":"Journal of Medicinal Chemistry"},{"issue":"8","key":"10.1016\/bs.vh.2018.10.008_bb0510","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure","volume":"23","author":"Yancy","year":"2017","journal-title":"Journal of Cardiac Failure"},{"issue":"4","key":"10.1016\/bs.vh.2018.10.008_bb0515","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/acsmedchemlett.5b00010","article-title":"Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists","volume":"6","author":"Yang","year":"2015","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"15","key":"10.1016\/bs.vh.2018.10.008_bb0520","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1016\/j.bmcl.2013.05.077","article-title":"Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists","volume":"23","author":"Yang","year":"2013","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"31","key":"10.1016\/bs.vh.2018.10.008_bb0525","doi-asserted-by":"crossref","first-page":"28468","DOI":"10.1074\/jbc.M504144200","article-title":"Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget","volume":"280","author":"Zhang","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"issue":"7","key":"10.1016\/bs.vh.2018.10.008_bb9800","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1093\/nar\/gkt103","article-title":"Specific recognition and stabilization of monomeric and multimeric G-quadruplexes by cationic porphyrin TMPipEOPP under molecular crowding conditions","volume":"41","author":"Zhu","year":"2013","journal-title":"Nucleic Acids Research"}],"container-title":["Vitamins and Hormones","Aldosterone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0083672918300803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0083672918300803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T01:46:45Z","timestamp":1548121605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0083672918300803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128177822"],"references-count":105,"URL":"https:\/\/doi.org\/10.1016\/bs.vh.2018.10.008","relation":{},"ISSN":["0083-6729"],"issn-type":[{"value":"0083-6729","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}